Lifileucel - Biologic Drug Details

Summary for lifileucel

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for lifileucel

Recent Clinical Trials for lifileucel

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Karam Khaddour	PHASE2
Iovance Biotherapeutics, Inc.	PHASE2
Immatics US, Inc.	PHASE3

See all lifileucel clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for lifileucel Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for lifileucel Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Iovance Biotherapeutics, Inc.	AMTAGVI	lifileucel	Suspension	125773		2038-01-18	DrugPatentWatch analysis and company disclosures
Iovance Biotherapeutics, Inc.	AMTAGVI	lifileucel	Suspension	125773		2036-01-14	DrugPatentWatch analysis and company disclosures
Iovance Biotherapeutics, Inc.	AMTAGVI	lifileucel	Suspension	125773		2037-12-25	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for lifileucel Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for lifileucel

Country	Patent Number	Estimated Expiration
Australia	2020349419
China	108884558
Spain	2994499

Lifileucel Market Analysis and Financial Projection

Last updated: February 16, 2026

What are the market dynamics influencing lifileucel?

Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) therapy exclusively developed for advanced melanoma. It operates within the rapidly evolving cell therapy landscape, which is driven by increasing demand for personalized immunotherapies and rising incidence rates of melanoma globally.

The key factors shaping its market environment include:

• Competitive landscape: Lifecycle management of existing immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) influences adoption. While these agents have established efficacy in melanoma, the emergence of TIL therapies offers alternative options for patients refractory to checkpoint inhibitors.

• Regulatory environment: The FDA granted lifileucel Orphan Drug designation for melanoma in 2020, which facilitates development through tax credits, regulatory exclusivity, and accelerated approval pathways.

• Manufacturing complexities: Personalized cell therapies involve complex, time-consuming manufacturing processes. Delays or scalability challenges impact launch timelines and pricing strategies.

• Pricing and reimbursement: High development costs lead to premium pricing. Reimbursement negotiations hinge on demonstrated clinical benefits over existing therapies and cost-effectiveness.

• Clinical trial activity: The ongoing Phase II/III trials are critical for approval and market penetration, with primary endpoints including overall response rate (ORR) and progression-free survival (PFS).

What is the current and projected financial trajectory for lifileucel?

Financial prospects for lifileucel derive from clinical milestones, regulatory approvals, and market adoption rate.

Revenue Estimates

• 2023: No approved product yet; revenue driven primarily by licensing fees or partnerships if collaborations exist. In the absence of commercial sales, revenues remain minimal.

• 2024–2025: Anticipated launch following potential FDA approval, assuming trial success. Initial revenues are expected between $150 million and $300 million, based on the unmet need for second-line melanoma treatments and existing pipeline data. These figures align with comparable TIL therapy companies, such as Iovance Biotherapeutics’ (IOVA) earlier estimates.

• 2026 and beyond: Growth trajectories depend on market penetration, vaccine combination strategies, and expanding indications. Sales could reach $500 million or more, with potential for accelerated growth upon expansion into other solid tumors.

Cost Structure and Profitability

• Manufacturing costs: Ranged between $50,000 and $100,000 per patient, depending on scale and automation. Efforts to scale manufacturing could lower costs.

• Pricing: Expected to be priced between $250,000 and $350,000 per treatment course to justify high costs associated with personalized therapy.

• Margins: Gross margins may initially be below 50%, improving with manufacturing efficiencies and scale.

Investment and Funding

• Significant investments are typical for cell therapies at this stage, with most funding directed toward clinical trials, manufacturing scale-up, and regulatory filings.

• Companies developing lifileucel often seek partnerships or licensing agreements with larger pharma entities to share costs and access broader markets.

What are the risks impacting the financial trajectory?

• Regulatory hurdles: Delays or rejection by regulators can suspend or restrict commercialization timelines.

• Manufacturing scalability: Continuous process improvements are necessary to meet demand without compromising quality, which affects costs and timelines.

• Clinical efficacy: Failure to demonstrate statistically significant benefit in pivotal trials will limit market access and revenues.

• Market competition: Efficacy of existing therapies, such as checkpoint inhibitors, poses an obstacle. New therapies like lifileucel need clear advantages to secure market share.

• Reimbursement landscape: Payers assess clinical value and cost-effectiveness stringently, potentially limiting reimbursement or requiring substantial demonstration of economic value.

How do market and financial dynamics compare to similar therapies?

Aspect	Lifileucel	TIL therapies (e.g., Iovance’s LN-145)	CAR-T therapies	Checkpoint inhibitors
Development stage	Late-stage clinical trials (Phase II/III)	Similar	Approved, commercialized	Market leader, mature
Pricing	$250K–$350K	Similar	$373K–$475K (CAR-Ts)	$100K–$150K/year
Manufacturing complexity	High	High	High	Low (off-the-shelf)
Reimbursement potential	High if efficacy proven	Similar	Established	High

Key takeaways

Lifileucel operates in a competitive, complex environment dominated by personalized immunotherapies. Regulatory progress and clinical trial results will influence its market entry and revenue potential. Manufacturing scalability and proven clinical benefit primarily drive long-term profitability. Market adoption hinges on demonstrating clear advantages over existing therapies, combined with favorable reimbursement policies.

Frequently Asked Questions

1. When could lifileucel receive FDA approval?
   Pending final trial results, approval could occur as early as 2024 or 2025.

2. What factors influence lifileucel’s pricing?
   Development costs, manufacturing complexity, competitor pricing, and perceived clinical value.

3. How does lifileucel compare cost-wise with CAR-T therapies?
   It is generally less expensive ($250K–$350K vs. CAR-Ts at ~$400K–$500K), but both face high manufacturing costs.

4. What major challenges could delay market entry?
   Delays in clinical trials, regulatory setbacks, manufacturing scalability issues.

5. Will lifileucel expand into other indications?
   Possibly, if Phase II/III trials demonstrate efficacy across other solid tumors, strategic expansion could occur.

---

Sources

[1] Bloomberg, industry reports, clinical trial registries, and regulatory filings on cellular therapies.